batimastat

batimastat

A non-cytotoxic inhibitor of matrix metalloproteinase, which inhibits matrix digestion, cell migration and smooth muscle cell migration without interfering with re-endothelialisation. It was first formulated as an anti-cancer drug and later studied for preventing in-stent restenosis, as it selectively targets migrating cells. The BRILLIANT-EU trial concluded that batimastat is no more effective than standard coated stents.

batimastat

Oncology An anticancer angiogenesis inhibitor of matrix metalloproteinase